Article Details

Atea and Roche's COVID-19 antiviral flunks phase 2, prompting switch that will delay pivotal data

Retrieved on: 2021-10-19 19:56:10

Tags for this article:

Click the tags to see associated articles and topics

Atea and Roche's COVID-19 antiviral flunks phase 2, prompting switch that will delay pivotal data. View article details on HISWAI: https://www.fiercebiotech.com/biotech/atea-and-roche-s-covid-19-antiviral-flunks-phase-2-prompting-switch-will-delay-pivotal-data

Excerpt

Atea Pharmaceuticals and Roche have suffered a big blow to their bid to bring an oral antiviral for COVID-19 to market. A phase 2 trial of the ...

Article found on: www.fiercebiotech.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up